PLI Schemes Boost ₹50,000+ Crore Pharma & MedTech Investment

India’s Production Linked Incentive (PLI) schemes are significantly expanding domestic manufacturing capabilities across bulk drugs, pharmaceuticals, and medical devices, driving investment and curbing import reliance. The PLI Scheme for Bulk Drugs, launched with a ₹6,940 crore ($948.09 million) outlay, targets 41 critical Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates. As of June 2026, actual investment has reached ₹5,210.74 crore ($548.68 million)—surpassing committed targets—with 39 commissioned projects producing 28 critical inputs, including fermentation-based compounds like Penicillin-G, Clavulanic Acid, and Rifampicin. This framework has generated cumulative sales of ₹3,792.49 crore ($399.33 million), including ₹560.16 crore ($58.98 million) in exports, while supporting over 5,100 domestic jobs. Concurrently, the ₹15,000 crore ($2.02 billion) PLI Scheme for Pharmaceuticals has mobilized massive capital toward biopharmaceuticals, complex generics, orphan drugs, and high-value formulations. Encompassing 55 selected applicants—including 20 MSMEs—the scheme attracted ₹46,744 crore ($4.92 billion) in actual investment against a ₹17,275 crore target, yielding ₹4.03 lakh crore ($42.42 billion) in cumulative sales, ₹2.57 lakh crore ($27.10 billion) in exports, and over 1.21 lakh jobs. Complementing these efforts, the ₹3,420 crore ($467.21 million) PLI Scheme for Medical Devices has operationalized domestic production for 57 advanced devices, such as MRI machines, CT scanners, Cath Labs, and linear accelerators, reinforcing India's industrial resilience across the healthcare supply chain.